PREVIEW: Pfizer Inc (PFE) earnings due 08/Feb at 11:45GMT/06:45EST

Pfizer Inc (PFE) Q4 2021 (USD): EPS (exp. 0.87/0.82 GAAP), Revenue (exp. 24.12bln)

KEY PHARMA SALES:

• BNT162/Comirnaty: (exp. 12.39bln)
• Prevnar: (exp. 1.67bln)
• Ibrance: (exp. 1.42bln)
• Eliquis: (exp. 1.38bln)
• Xeljanz: (exp. 0.64bln)

DIVIDEND:

• FY Dividend: (exp. 1.59)

EPS GUIDANCE:

• Q1 2022 EPS View: (exp. 1.55/1.48 GAAP)
• FY 2022 EPS View: (exp. 6.69/5.92 GAAP)

REVENUE GUIDANCE:

• Q1 2022 Revenue View: (exp. 24.79bln)
• FY 2022 Revenue View: (exp. 105.48bln)

INDEX WEIGHT:

• 0.8% SPX weight
• Sector/Industry: Health Care/Pharmaceuticals

BROKER RATING:

• Avg Rating: 'Buy'
• Avg Price Target: USD 59.68
• Price Target Changes (last 30 days): 5 upward vs 3 downward